When a CEO buys stock in their own company, it’s one of the clearest signals of confidence an investor can find. These trades are public, trackable, and often reveal when insiders believe Wall Street is missing something.
Valuing a stock is part math, part mindset, and even small errors can lead to big losses or missed opportunities. This guide breaks down five common mistakes investors make when estimating fair value and shows how to avoid them by focusing on cash flow, context, and disciplined assumptions.
Babcock’s turnaround story is gathering momentum. Stronger margins, a cleaner balance sheet, and an upgraded medium-term outlook signal that the defence contractor is finally converting years of restructuring into real cash and shareholder returns.
Greggs’ latest results show short-term cost pressure but long-term potential. With new capacity, technology, and formats on the way, 2025 may mark a turning point rather than a step back.
HSBC’s restructuring is showing results, but the gains are uneven. The bank continues to grow its wealth and markets businesses, even as impairments and one-time losses weigh on profits.
GSK’s transformation into a pure-play biopharma company continues to show steady progress. Specialty Medicines and Vaccines are now driving the majority of sales and profits, even as the company contends with a sharp drop in net income and margin pressure.
Experian’s latest results show a company still growing, still investing, and still leading its category, but also feeling the cost of that ambition. While revenue growth remains solid, earnings came in light and margins narrowed, raising the question: Is this a temporary dip or the start of a slower cycle?
Unilever’s turnaround remains a work in progress. The company is growing modestly, simplifying its portfolio, and preparing to spin off its Ice Cream division, but the financial story is still mixed.
Barclays’ latest results highlight a bank that’s profitable, disciplined, and clearly executing on its three-year plan. The only problem? It’s all going according to plan, and that left investors wanting more.
BT Group’s latest results show a company that’s tightening up and leaning into efficiency. Profits are up, margins have improved, and cost savings are ahead of plan. But with revenue slipping and heavy infrastructure spending still on the books, this remains a story of stability rather than expansion.
Rolls-Royce’s turnaround story has accelerated faster than many expected. With profitability, cash flow, and margins all climbing sharply in 2025, the British engineering giant enters 2026 on solid footing, and investors are beginning to take notice.
Burberry’s fiscal 2024/25 results painted a tough picture: sales dropped, profits collapsed, and the brand’s repositioning efforts tested investor patience. Yet with new creative direction, leaner inventories, and a cleaner balance sheet, there’s a growing sense that this may mark the low point before a rebound.
AstraZeneca delivered another year of strong top-line growth in 2024, fueled by blockbuster oncology drugs and expanding partnerships. Yet with profit margins holding steady and EPS growth trailing revenue gains, investors are now weighing whether the company’s next phase will be defined by expansion or normalization.
Shell’s 2025 results show a company that has mastered capital discipline and cash generation, even as the energy transition challenges its long-term identity. With oil prices steady, LNG surging, and buybacks driving shareholder yield, Shell remains powerful, but its growth story now looks more like optimization than expansion.
Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.
